JP Morgan Private Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,832
| Closed | -$204K | – | 1757 |
|
|
2023
Q2 | $204K | Sell |
2,832
-640
| -18% | -$48K | ﹤0.01% | 1386 |
|
|
2023
Q1 | $255K | Sell |
3,472
-146
| -4% | -$10.4K | ﹤0.01% | 1741 |
|
|
2022
Q4 | $242K | Sell |
3,618
-2,437
| -40% | -$158K | ﹤0.01% | 1739 |
|
|
2022
Q3 | $325K | Buy |
6,055
+368
| +6% | +$21.6K | ﹤0.01% | 1624 |
|
|
2022
Q2 | $317K | Sell |
5,687
-238
| -4% | -$13.5K | ﹤0.01% | 1620 |
|
|
2022
Q1 | $416K | Sell |
5,925
-2,061
| -26% | -$150K | ﹤0.01% | 1611 |
|
|
2021
Q4 | $770K | Sell |
7,986
-576
| -7% | -$53.2K | ﹤0.01% | 1374 |
|
|
2021
Q3 | $744K | Sell |
8,562
-57
| -0.7% | -$4.41K | ﹤0.01% | 1344 |
|
|
2021
Q2 | $705K | Sell |
8,619
-167
| -2% | -$13.9K | ﹤0.01% | 1352 |
|
|
2021
Q1 | $836K | Sell |
8,786
-1,726
| -16% | -$163K | ﹤0.01% | 1121 |
|
|
2020
Q4 | $652K | Sell |
10,512
-509
| -5% | -$29K | ﹤0.01% | 1184 |
|
|
2020
Q3 | $655K | Sell |
11,021
-396
| -3% | -$27K | ﹤0.01% | 1050 |
|
|
2020
Q2 | $797K | Buy |
11,417
+114
| +1% | +$7.23K | ﹤0.01% | 894 |
|
|
2020
Q1 | $513K | Buy |
11,303
+2,368
| +27% | +$134K | ﹤0.01% | 918 |
|
|
2019
Q4 | $581K | Sell |
8,935
-132
| -1% | -$8.82K | ﹤0.01% | 989 |
|
|
2019
Q3 | $563K | Buy |
9,067
+3,317
| +58% | +$208K | ﹤0.01% | 964 |
|
|
2019
Q2 | $409K | Sell |
5,750
-80
| -1% | -$5.89K | ﹤0.01% | 1050 |
|
|
2019
Q1 | $457K | Buy |
5,830
+672
| +13% | +$50.9K | ﹤0.01% | 1069 |
|
|
2018
Q4 | $437K | Buy |
5,158
+22
| +0.4% | +$2.35K | ﹤0.01% | 1021 |
|
|
2018
Q3 | $879K | Sell |
5,136
-4,591
| -47% | -$692K | ﹤0.01% | 865 |
|
|
2018
Q2 | $1.26M | Buy |
9,727
+377
| +4% | +$42.1K | 0.01% | 707 |
|
|
2018
Q1 | $963K | Buy |
9,350
+123
| +1% | +$12.2K | 0.01% | 659 |
|
|
2017
Q4 | $788K | Sell |
9,227
-59
| -0.6% | -$5.11K | 0.01% | 724 |
|
|
2017
Q3 | $789K | Buy |
9,286
+755
| +9% | +$59.8K | 0.01% | 696 |
|
|
2017
Q2 | $646K | Buy |
8,531
+546
| +7% | +$38.2K | ﹤0.01% | 750 |
|
|
2017
Q1 | $527K | Buy |
+7,985
| New | +$525K | ﹤0.01% | 829 |
|
|
2016
Q3 | – | Sell |
-3,041
| Closed | -$226K | – | 1249 |
|
|
2016
Q2 | $226K | Sell |
3,041
-3,012
| -50% | -$224K | ﹤0.01% | 1107 |
|
|
2016
Q1 | $404K | Buy |
6,053
+2,613
| +76% | +$159K | ﹤0.01% | 819 |
|
|
2015
Q4 | $233K | Buy |
+3,440
| New | +$212K | ﹤0.01% | 971 |
|
|
2015
Q3 | – | Sell |
-3,847
| Closed | -$243K | – | 1099 |
|
|
2015
Q2 | $243K | Buy |
+3,847
| New | +$210K | ﹤0.01% | 919 |
|
Other funds holding LGND
SIMG
SDJVC
CC
JP Morgan Private Wealth Advisors's LGND Position: Q3 2023 in Review
JP Morgan Private Wealth Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2023, closing a stake of 2,832 shares — an estimated $204K sold.
JP Morgan Private Wealth Advisors first reported a position in LGND in Q2 2015 and held it in 30 quarters. The position peaked at $1.26M in Q2 2018. 196 funds tracked by Wall St. Rank hold LGND as of Q3 2023.
- JP Morgan Private Wealth Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
- JP Morgan Private Wealth Advisors sold 2,832 Ligand Pharmaceuticals shares in Q3 2023, an estimated $204K.
- JP Morgan Private Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 30 quarters.
- JP Morgan Private Wealth Advisors's Ligand Pharmaceuticals position peaked at $1.26M in Q2 2018.
- 196 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2023.
Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.